drugset / Trial / NCT02672540
A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis who are admitted to the hospital for treatment.
Timeline
- Start
- 2016-07
- Primary completion
- 2017-05-31
- Completion
- 2017-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegylated carboxyhemoglobin bovine | Protein / enzyme biologic | 320 mg/kg | Other |